These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients. Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855 [TBL] [Abstract][Full Text] [Related]
6. Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats. de Araújo DP; Camboim TGM; Silva APM; Silva CDF; de Sousa RC; Barbosa MDA; Oliveira LC; Cavalcanti JRLP; Lucena EES; Guzen FP Can J Physiol Pharmacol; 2017 Jul; 95(7):837-843. PubMed ID: 28329449 [TBL] [Abstract][Full Text] [Related]
7. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Christoffersen CL; Meltzer LT Neuropsychopharmacology; 1998 May; 18(5):399-402. PubMed ID: 9536454 [TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic approaches of natural oil from black seeds and its underlying mechanisms against kidney dysfunctions in haloperidol-induced male rats. Akintunde JK; Abubakar OK Drug Metab Pers Ther; 2017 May; 32(2):97-107. PubMed ID: 28384101 [TBL] [Abstract][Full Text] [Related]
9. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats. Shireen E; Naeem S; Inam QU; Haleem DJ Pak J Pharm Sci; 2013 Mar; 26(2):271-6. PubMed ID: 23455196 [TBL] [Abstract][Full Text] [Related]
10. [The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics]. Popov MIu Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(6):28-33. PubMed ID: 18577931 [TBL] [Abstract][Full Text] [Related]
11. Neurochemical and behavioral effects of Nigella sativa and Olea europaea oil in rats. Cheema MAR; Nawaz S; Gul S; Salman T; Naqvi S; Dar A; Haleem DJ Nutr Neurosci; 2018 Apr; 21(3):185-194. PubMed ID: 27868798 [TBL] [Abstract][Full Text] [Related]
12. Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. Samad N; Haleem MA; Haleem DJ Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1467-71. PubMed ID: 27592482 [TBL] [Abstract][Full Text] [Related]
13. Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice. Arora D; Mudgal J; Nampoothiri M; Mallik SB; Kinra M; Hall S; Anoopkumar-Dukie S; Grant GD; Rao CM Metab Brain Dis; 2018 Aug; 33(4):1045-1051. PubMed ID: 29516413 [TBL] [Abstract][Full Text] [Related]
14. An animal model to study the molecular basis of tardive dyskinesia. Bishnoi M; Boparai RK Methods Mol Biol; 2012; 829():193-201. PubMed ID: 22231815 [TBL] [Abstract][Full Text] [Related]
15. Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Ikram H; Samad N; Haleem DJ Pak J Pharm Sci; 2007 Jul; 20(3):188-95. PubMed ID: 17545102 [TBL] [Abstract][Full Text] [Related]
16. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Allan ER; Sison CE; Alpert M; Connolly B; Crichton J Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201 [TBL] [Abstract][Full Text] [Related]
17. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Andrew HG Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668 [TBL] [Abstract][Full Text] [Related]
18. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Tada M; Shirakawa K; Matsuoka N; Mutoh S Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255 [TBL] [Abstract][Full Text] [Related]
19. Anandamide attenuates haloperidol-induced vacuous chewing movements in rats. Röpke J; Busanello A; Leal CQ; de Moraes Reis E; de Freitas CM; Villarinho JG; Figueira FH; Mello CF; Ferreira J; Fachinetto R Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():195-9. PubMed ID: 24747871 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms. Murphy JE; Stewart RB Am J Hosp Pharm; 1979 May; 36(5):641-4. PubMed ID: 36755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]